Furthermore, given its ability to influence the synthesis of estrogens and the presence of melatonin receptors in breast tissue, melatonin has been employed in clinical studies as therapeutic agent in estrogen receptors (ER)-positive breast cancer, where it reduces the estrogenic pathway activation by down-regulating the ER receptor transcription [166]. Here, ESR1 is linked to breast cancer.